{"id":20069,"date":"2025-05-16T18:46:28","date_gmt":"2025-05-16T23:46:28","guid":{"rendered":"https:\/\/zaracaytv.com\/?p=20069"},"modified":"2025-05-16T18:47:18","modified_gmt":"2025-05-16T23:47:18","slug":"nueva-terapia-reduce-casi-a-la-mitad-el-colesterol-malo-en-pacientes-cardiacos","status":"publish","type":"post","link":"https:\/\/zaracaytv.com\/?p=20069","title":{"rendered":"NUEVA TERAPIA REDUCE CASI A LA MITAD EL COLESTEROL \u201cMALO\u201d EN PACIENTES CARD\u00cdACOS"},"content":{"rendered":"<body><p><\/p>\n<p class=\"\" data-start=\"216\" data-end=\"592\">Un estudio cl\u00ednico liderado por Cleveland Clinic revel\u00f3 que la combinaci\u00f3n de dos medicamentos, obicetrapib y ezetimiba, logr\u00f3 reducir en un 48.6 % los niveles de colesterol LDL, conocido como colesterol \u201cmalo\u201d, en pacientes con afecciones card\u00edacas, tras <img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-20070 alignright\" src=\"https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45-300x200.jpeg\" alt=\"\" width=\"300\" height=\"200\" loading=\"lazy\" srcset=\"https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45-300x200.jpeg 300w, https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45-1024x682.jpeg 1024w, https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45-768x512.jpeg 768w, https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45-495x330.jpeg 495w, https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45-270x180.jpeg 270w, https:\/\/zaracaytv.com\/wp-content\/uploads\/2025\/05\/WhatsApp-Image-2025-05-16-at-18.04.45.jpeg 1280w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>solo tres meses de tratamiento. La terapia result\u00f3 m\u00e1s efectiva que el uso individual de cualquiera de los dos f\u00e1rmacos.<\/p>\n<p class=\"\" data-start=\"594\" data-end=\"958\">Los resultados, presentados en la reuni\u00f3n anual de la European Atherosclerosis Society y publicados en <em data-start=\"697\" data-end=\"709\">The Lancet<\/em>, ofrecen una alternativa prometedora para quienes, pese a seguir tratamientos con estatinas, no alcanzan sus metas de reducci\u00f3n de colesterol. El estudio involucr\u00f3 a 407 pacientes con niveles elevados de LDL pese a recibir terapias m\u00e1ximas previas.<\/p>\n<p class=\"\" data-start=\"960\" data-end=\"1369\">Los especialistas destacaron que esta combinaci\u00f3n podr\u00eda representar un gran avance para pacientes con alto riesgo cardiovascular que requieren medidas m\u00e1s agresivas. El Dr. Steven Nissen, director acad\u00e9mico del Heart, Vascular &amp; Thoracic Institute de Cleveland Clinic, se\u00f1al\u00f3 que, si la terapia recibe aprobaci\u00f3n regulatoria, podr\u00eda facilitar que m\u00e1s pacientes alcancen sus objetivos de salud cardiovascular.<\/p>\n<p><\/p>\n<\/body>","protected":false},"excerpt":{"rendered":"<p>Un estudio cl\u00ednico liderado por Cleveland Clinic revel\u00f3 que la combinaci\u00f3n de dos medicamentos, obicetrapib y ezetimiba, logr\u00f3 reducir en un 48.6 % los niveles de colesterol LDL, conocido como colesterol \u201cmalo\u201d, en pacientes con afecciones card\u00edacas, tras solo tres meses de tratamiento. La terapia result\u00f3 m\u00e1s efectiva que el uso individual de cualquiera de [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":20070,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_joinchat":[],"footnotes":""},"categories":[40],"tags":[],"class_list":["post-20069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mundo"],"_links":{"self":[{"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/posts\/20069","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20069"}],"version-history":[{"count":1,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/posts\/20069\/revisions"}],"predecessor-version":[{"id":20071,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/posts\/20069\/revisions\/20071"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=\/wp\/v2\/media\/20070"}],"wp:attachment":[{"href":"https:\/\/zaracaytv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20069"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20069"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zaracaytv.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20069"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}